Search

Your search keyword '"Neha Mehta-Shah"' showing total 11 results
Start Over Author "Neha Mehta-Shah" Publisher wiley
11 results on '"Neha Mehta-Shah"'

2. P1182: A PROSPECTIVE STUDY OF TCR MEASURABLE RESIDUAL DISEASE IN PERIPHERAL T-CELL LYMPHOMA

Author

Austin Jacobsen, Ying Huang, Natalie Hill, Karina Elias, Matthew Holman, Skyler Gordon, Nicole Foley, David Russler-Germain, Marcus Watkins, Eric D. Jacobsen, Alison Moskowitz, Amanda Cashen, Todd A. Fehniger, Brad Kahl, Armin Ghobadi, Beth Reagan, Anne Fischer, Fei Wan, Steven Horwitz, and Neha Mehta-Shah

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

4. Clinical severity measures and quality‐of‐life burden in patients with mycosis fungoides and Sézary syndrome: comparison of generic and dermatology‐specific instruments

Author

Amy Musiek, Neha Mehta-Shah, A.R. Rosenberg, C. Herbosa, and Yevgeniy R. Semenov

Subjects
medicine.medical_specialty, Skin Neoplasms, Visual analogue scale, Population, Dermatology, Disease, Disease cluster, 030207 dermatology & venereal diseases, 03 medical and health sciences, Mycosis Fungoides, 0302 clinical medicine, Quality of life, medicine, Humans, Sezary Syndrome, Stage (cooking), education, Mycosis fungoides, education.field_of_study, business.industry, medicine.disease, humanities, Infectious Diseases, 030220 oncology & carcinogenesis, Quality of Life, business, Health Utilities Index
Abstract

BACKGROUND Given the severe symptom burden and chronic nature of mycosis fungoides (MF) and Sezary syndrome (SS), effective assessment of quality of life (QoL) is essential to guiding patient-centred care in this population. In this study, we aim to provide a comprehensive assessment of QoL in early- and advanced-stage MF/SS and to assess the correlation of traditional measures of clinical severity with QoL measures. METHODS Between July 2017 and April 2019, outpatients at an academic medical centre with either MF/SS (n = 115) or general dermatology concerns (n = 115) completed generic and dermatology-specific QoL instruments [Health Utilities Index Mark 3 (HUI3), RAND 36-Item Short-Form Health Survey (SF-36), Skindex-29, visual analogue scale for itch (VAS itch) and 5-D pruritus scale]. The mean scores of MF/SS patients were compared to that of controls using multivariable regression models adjusted for demographics and medical comorbidities. Cluster analysis of the QoL instruments and clinical severity measures (e.g. stage and body-surface-area involvement) was performed. RESULTS Patients with MF/SS scored significantly worse than controls on all QoL instruments used, with advanced-stage (IIB-IVB) disease having the worst QoL impairment. Early-stage (IA-IIA) and advanced-stage MF/SS patients had significantly reduced overall health status (HUI3; P

Published
2020
Full Text
View/download PDF

5. THE COMBINATION OF DUVELISIB AND ROMIDEPSIN (DR) IS HIGHLY ACTIVE AGAINST RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA WITH LOW RATES OF TRANSAMINITIS: FINAL RESULTS

Author

S. Fang, Youn H. Kim, Neha Mehta-Shah, William Blouin, C. Maccaro, Steve Horwitz, Helen Hancock, A.J. Moskowitz, Theresa Davey, Sunyoung Ryu, Patricia L. Myskowski, Ariela Noy, Michael S. Khodadoust, Lorenzo Falchi, David J. Straus, Natasha Galasso, David C. Fisher, Ahmet Dogan, E. Cathcart, Eric D. Jacobsen, Anita Kumar, J. Schwieterman, Leslie Perez, Nivetha Ganesan, Esther Drill, and David M. Weinstock

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Hematology, General Medicine, medicine.disease, Duvelisib, Peripheral T-cell lymphoma, Romidepsin, chemistry.chemical_compound, chemistry, Internal medicine, Relapsed refractory, medicine, Transaminitis, business, medicine.drug
Published
2021
Full Text
View/download PDF

6. NIVOLUMAB PLUS BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: EXTENDED FOLLOW‐UP FROM THE PHASE 2 CHECKMATE 436 STUDY

Author

Neha Mehta-Shah, Pauline Brice, Justin Kline, John Kuruvilla, Paul M. Barr, David Cunningham, Nathalie A. Johnson, Giuseppe Gritti, Armando Santoro, Michelle A. Fanale, P. L. Zinzani, A.J. Moskowitz, and Stephen Francis

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Checkmate, Hematology, General Medicine, Internal medicine, Relapsed refractory, medicine, Primary Mediastinal Large B-Cell Lymphoma, Nivolumab, Brentuximab vedotin, business, medicine.drug
Published
2021
Full Text
View/download PDF

7. PHASE I/II STUDY OF CHOEP PLUS LENALIDOMIDE AS INITIAL THERAPY FOR PATIENTS WITH STAGE II-IV PERIPHERAL T-CELL LYMPHOMA: PHASE II RESULTS

Author

Matthew A. Lunning, Jasmine Zain, Mary Jo Lechowicz, Julie M. Vose, Steve Horwitz, A.J. Moskowitz, S. M. Ansell, R. Advani, Neha Mehta-Shah, Brad Haverkos, Hun J. Lee, L. Lyden, and Peggy Heires

Subjects
Cancer Research, business.industry, Hematology, General Medicine, Stage ii, medicine.disease, Peripheral T-cell lymphoma, Phase i ii, Oncology, Phase (matter), Cancer research, Medicine, business, Initial therapy, Lenalidomide, medicine.drug
Published
2019
Full Text
View/download PDF

8. MULTI-CENTER PHASE II STUDY OF ORAL AZACITIDINE (CC-486) PLUS CHOP AS INITIAL TREATMENT FOR PERIPHERAL T-CELL LYMPHOMA

Author

L. Benderoff, John P. Leonard, Morton Coleman, K. Van Besien, Lubomir Sokol, Jia Ruan, Giorgio Inghirami, Peter Martin, Leandro Cerchietti, Neha Mehta-Shah, A.J. Moskowitz, Sarah C. Rutherford, and Amelyn Rodriguez

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Phases of clinical research, Hematology, General Medicine, CHOP, medicine.disease, Peripheral T-cell lymphoma, Oral Azacitidine, Internal medicine, Medicine, Initial treatment, Center (algebra and category theory), business
Published
2019
Full Text
View/download PDF

9. Duvelisib, an oral dual PI3K-δ,γ inhibitor, efficacy and safety in patients with relapsed or refractory (RR) peripheral T-cell lymphoma: rationale for the phase 2 PRIMO trial

Author

Pierluigi Porcu, David M. Weinstock, E. Jacobsen, Youn H. Kim, Michael S. Khodadoust, Francine M. Foss, Jonathan E. Brammer, Steve Horwitz, A.J. Moskowitz, Neha Mehta-Shah, M. Baglio, Hagop Youssoufian, and Stephanie Lustgarten

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Hematology, General Medicine, medicine.disease, Duvelisib, Peripheral T-cell lymphoma, chemistry.chemical_compound, Refractory, chemistry, Internal medicine, medicine, In patient, business, PI3K/AKT/mTOR pathway
Published
2019
Full Text
View/download PDF

10. NIVOLUMAB COMBINED WITH BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: EFFICACY AND SAFETY FROM THE PHASE 2 CHECKMATE 436 STUDY

Author

Stephen Francis, John Kuruvilla, Paul M. Barr, Manish Sharma, Nathalie A. Johnson, P. L. Zinzani, Armando Santoro, Thomas Manley, A.J. Moskowitz, Pauline Brice, Giuseppe Gritti, Justin Kline, David Cunningham, and Neha Mehta-Shah

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Checkmate, Hematology, General Medicine, Internal medicine, Relapsed refractory, Medicine, Primary Mediastinal Large B-Cell Lymphoma, Nivolumab, business, Brentuximab vedotin, medicine.drug
Published
2019
Full Text
View/download PDF

11. PHASE I/II STUDY OF CHOEP PLUS LENALIDOMIDE AS INITIAL THERAPY FOR PATIENTS WITH STAGE II-IV PERIPHERAL T-CELL NON-HODGKIN LYMPHOMA: PHASE I RESULTS FROM THE T-CELL CONSORTIUM

Author

Yasuhiro Oki, Jasmine Zain, Matthew A. Lunning, Anne W. Beaven, Steve Horwitz, A.J. Moskowitz, Brad M. Haverkos, S. M. Ansell, Mary Jo Lechowicz, Neha Mehta-Shah, and Ranjana H. Advani

Subjects
Cancer Research, business.industry, T cell, Hematology, General Medicine, Stage ii, Peripheral, 03 medical and health sciences, 0302 clinical medicine, T-Cell Non-Hodgkin Lymphoma, Phase i ii, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Phase (matter), Cancer research, medicine, business, Initial therapy, 030215 immunology, Lenalidomide, medicine.drug
Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results